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The role of the matrix (MA) domain of simian immunodeficiency virus (SIV) and bovine leukaemia virus (BLV) Gag in the
assembly of virus-like particles (VLP) in insect cells has been investigated. Wild-type SIV and BLV Gag assembled to form
discrete VLP structures typical of many retroviruses analysed by similar systems. When amino acids predicated by the
three-dimensional structure to be at the interface of SIV MA monomers were deleted, VLP assembly was abolished
consistent with a role for MA multimerization in assembly. When amino acids predicted to be in the analogous positions in
BLV MA were mutated, however, VLP assembly was not affected. These data indicate that the models of assembly derivedINTRODUCTION
The retroviral Gag protein is the minimal particle-form-
ing unit of the virus (Delchambre et al., 1989; Gheysen et
al., 1989; Haffar et al., 1990; Mergener et al., 1992; Smith
et al., 1990). Particle assembly begins with association of
the Gag polyprotein with the host cell plasma membrane
and is followed by immature virus-like particle budding
from the expressing cell. The particle finally becomes
infectious after a maturation reaction which begins at, or
soon after, budding and in which the viral protease
cleaves the Gag polyprotein into its constituent parts, the
matrix (MA), capsid (CA), and nucleocapsid (NC) pro-
teins. Of these proteins, MA provides a significant struc-
tural component of the virus and has a multifunctional
role in viral assembly and morphogenesis.
The three-dimensional structure of the MA proteins of
lentiviruses such as simian (SIV) and human (HIV) im-
munodeficiency viruses (Hill et al., 1996; Rao et al., 1995)
have provided structural explanations for the various
roles played by MA in virion assembly and associated
events. These include incorporation of the envelope gly-
coproteins, membrane targeting, and morphogenesis
(Chazal et al., 1994; Dorfman et al., 1994; Freed and
Martin, 1995; Gonzalez et al., 1993; Mammano et al.,
1995; Morikawa et al., 1995; Rhee and Hunter, 1991; Yu et
al., 1992; Yuan et al., 1993). Both the SIV and the HIV MAs
are trimeric (Belyaev et al., 1994; Hill et al., 1996; Rao et© 2002 Elsevier Science (USA)
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48al., 1995) and the features of the trimer have provided
rational explanations for Gag interaction with the inner
viral membrane and with Env (Hill et al., 1996; Rao et al.,
1995). The trimeric structure of MA is also consistent
with current models of virus assembly (Forster et al.,
2000).
The three dimensional solution structure of bovine
(BLV) leukaemia virus MA monomers, obtained by het-
eronuclear magnetic resonance (NMR), reveals a much
simpler molecule than the SIV MA monomer but has
been modelled, on the basis of the SIV MA trimer, to
provide a very similar trimeric structure (Matthews et al.,
1996). Similarly, the monomeric MA domain of Mason-
Pfizer monkey virus (M-PMV), a type D retrovirus, has
been also modelled as a trimer (Conte et al., 1997). The
obvious structural relatedness evident in the MA do-
mains from diverse retroviruses, despite low sequence
homology, has also been shown to extend to other Gag
domains (Turner and Summers, 1999).
In our previous article we have shown that MA and CA
domains could efficiently be exchanged between these
two members of the lentivirus and leukovirus group of
retroviruses without any perturbation of Gag assembly
and budding (Kakker et al., 1999). However, the extent to
which MA trimerization is an assembly intermediate
shared by both groups was not investigated. In the
present study, mutagenesis and expression of the SIV
MA domain of Gag has been used to confirm the role of
the MA trimer in VLP assembly. In addition, based on thefrom one model retrovirus may not necessarily apply to mor
in equivalent Gag domains. © 2002 Elsevier Science (USA)
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proposed trimeric BLV MA structure (Matthews et al.,
1996), equivalent mutations in the MA domain of BLVe dista
Gag were constructed and their effect on BLV VLP as-
sembly assessed.
RESULTS AND DISCUSSION
Construction and expression of mutant SIV Gag
The SIV MA trimer has been suggested to be a fun-
damental assembly intermediate of the Gag shell (Rao et
al., 1995). The SIV MA is predominantly helical, consist-
ing of seven helices (H1 to H7) with helix 4 critical for
positioning the interacting residues for presentation to
the adjacent molecule. The trimer is held together by
hydrogen bonds between Gly45-Leu46-Ala47 of one mono-
mer and Ser72-Gly71-Thr70 of the adjacent monomer. To
investigate the role of residues Gly45, Leu46, Ala47 in MA
oligomerization in context of the full-length SIV Gag, four
recombinant baculoviruses were constructed that ex-
pressed SIV Gag and mutants thereof. AcSgag encoded
the wild-type SIV Gag while AcSgag45–47, AcSgag45–46,
and AcSgag45 encoded SIV Gag proteins lacking three
(Gly45-Leu46-Ala47), two (Gly45, Leu46), or one (Gly45) MA
residue, respectively. To ensure all the mutant Gag pro-
teins were expressed at a significant level and to assess
assembly and release, Spodoptera frugiperda (Sf9) cells
were infected with each recombinant baculovirus and
the expression and distribution of SIV wild-type or mutant
Gag protein was examined by SDS–PAGE and Western
blot. AcSgag-infected Sf cells expressed a protein of
molecular weight of 57 kDa that was recognised specif-
ically by a monkey anti-SIV serum in Western blot anal-
ysis (Fig. 1) and corresponded to a size which agreed
with that previously published for unmodified SIV Gag
(Delchambre et al., 1989). No SIV-related proteins were
detected in control AcMNPV-infected Sf cells. Recombi-
nant viruses AcSgag45–47, AcSgag45–46, and AcSgag45
also expressed a 57-kDa protein that was specifically
recognised by an anti-SIV serum (Fig. 1) in keeping with
the minor deletions of sequence made during mutagen-
esis.
AcSgag-infected cell supernatants showed the pres-
ence of abundant SIV Pr57Gag polyprotein typical of the
phenotype of VLP competent retroviruses, and absent
from the AcMNPV control (Fig. 1). Similarly, AcSgag45–46
or AcSgag45-infected cells contained Gag antigen at
levels similar to those observed for the parental SIV
Pr57Gag. In contrast, supernatants from Sf cells infected
with AcSgag45–47 showed no evidence of Gag protein
(Fig. 1), suggesting removal of MA amino acids 45–47
prevented Gag assembly or release.
SIV Gag45–47 does not assemble into VLPs
To further characterise the wild-type and mutant SIV
Gag polyproteins expressed in this system, insect cells
infected with each recombinant virus were fixed at 2
days postinfection and processed for thin-section elec-
tron microscopy (Hockley et al., 1994). Numerous VLPs at
different stages of assembly and budding were detect-
able at the plasma membrane of Sf9 cells infected with
AcSgag (Fig. 2A), AcSgag45–46 (Fig. 2C), or AcSgag45
(Fig. 2D). However, no retrovirus-like budding particles
were detected in sections of AcSgag45–47-infected Sf
cells (Fig. 2B), confirming the VLP negative phenotype of
this mutation and in marked contrast to deletion of one
(AcSgag45) or two (AcSgag45–46) residues at the mono-
mer–monomer interface. Low electron density at the
plasma membrane of AcSgag45–47-expressing cells sug-
FIG. 2. Electron micrographs of thin sections of Sf cells infected
recombinant baculovirus expressing SIV Pr57Gag (quadrant A); SIV
Gag45–47 (quadrant B); SIV Gag45–46 (quadrant C); and SIV Gag45
(quadrant D). Note the absence of budding or free VLP in quadrant B.
The bar represents 100 nm.
FIG. 1. Western blot analysis of wild-type and mutant SIV Gag ex-
pression and particle release in insect cells. Cell lysates and super-
natants were resolved by 10% SDS–PAGE and immunoblotted using a
monkey anti-SIV serum. The five virus-infected samples, four tests, and
a control are indicated above the lanes. Lanes 1, 3, 5, 7, and 9 are cell
lysates. Lanes 2, 4, 6, 8 and 10 are supernatants. The identity of SIV
Pr57Gag is indicated by the arrowhead.
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gested that non-membrane-localised Gag may be largely
degraded, confirming data obtained recently by pulse
chase experiments (Tritel and Resh, 2000). As the posi-
tively charged flat surface produced by MA trimerisation
has been suggested to be the basis of membrane local-
isation (Hill et al., 1996; Zhou et al., 1994), an indirect
consequence of failure to trimerize could be reduced
membrane residency. Thus, mutations constructed on
the basis of the SIV MA crystal structure could be inter-
preted as providing tacit support for a role of MA trimer-
ization, in the context of full-length Pr57Gag, in SIV VLP
assembly.
Construction and expression of mutant BLV Gag
As the data obtained following targeted mutagenesis
of the MA domain of SIV Gag provided a plausible role
for the SIV MA trimer interface in VLP assembly, the
extent to which this was also the case for BLV Gag was
investigated. The BLV MA monomer consists of four
-helices: A (Ser14 to Asn29), B (Ser32 to Gln51), C (Phe57 to
Cys65), and D (Val73 to Leu85), separated by short, semi-
structured loops (Matthews et al., 1996), a topology sim-
ilar to the first four -helices of the SIV MA (Fig. 3). In
addition, there is a striking similarity between the trimer
interface loops (Gly45-Ala47 and Thr70-Ser72) of SIV MA
and the loops at the junctions of helices B-C and C-D in
BLV MA and spanning the regions around Gln51-Lys69
(Fig. 3). In the proposed trimeric BLV MA, residues Lys49-
Gln51 in the loop between helices B and C of one mono-
mer, and Pro67-Arg72 between helices C and D of the
adjacent monomer, have been postulated to form the
trimer interface (Matthews et al., 1996). To assess the
role of these residues in BLV VLP assembly, recombinant
baculoviruses were constructed in which a deletion win-
dow of between three and five amino acids was moved
through these proposed interaction domains. In addition,
a double deletion, in which key residues on opposing
faces of the MA monomer were removed, was also
constructed. AcBgag49–51 lacked Lys49-Gln51; AcBgag66–68
lacked Pro66-Gly68; AcBgag67–69 lacked Pro67-Lys69;
AcBgag68–70 lacked Gly68-Phe70; AcBgag68–71 lacked
Gly68-Gly71, and AcBgag68–72 lacked Gly68-Arg72. The
double-deletion AcBgag49–51,68–72 was also produced.
Recombinant baculoviruses were isolated and ampli-
fied as described before high multiplicity infections of
Sf9 cells and analysis of their expression profile by
SDS–PAGE and Western blot.
Recombinant baculovirus AcBgag49–51 expressed a re-
combinant protein of 44 kDa that was identified spe-
cifically in cell lysates on Western blots using a rabbit
anti-BLV serum (Fig. 4). The identified band comigrated
with wild-type BLV Pr44Gag expressed in BLV-infected
FIG. 3. Backbone structures of the SIV MA trimer (above) and the proposed BLV MA trimer model (below). Areas of monomer–monomer interaction
are shown enlarged on the right.
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foetal lamb kidney cells (not shown). Wild-type AcMNPV-
infected cells did not express any anti-BLV reactive pro-
teins (Fig. 4). Recombinant baculoviruses AcBgag66–68,
AcBgag67–69, AcBgag68–70, AcBgag68–71, or AcBgag68–72
also expressed a BLV protein of 44 kDa that was
similarly detected by a BLV serum in Western blots and
typified by the profiles obtained for AcBgag68–70 and
AcBgag49–51-infected cells (Fig. 4, lanes 3 and 5).
To assess the ability of wild-type and mutant BLV Gag
to assemble into VLPs, particulate material in the super-
natant from cells infected with each recombinant was
concentrated by centrifugation through a sucrose cush-
ion, resuspended, and analysed by SDS–PAGE and
Western blot. Each mutant showed evidence of abundant
synthesis of Gag antigen that was released into the
supernatant of infected cells (Fig. 4, lanes 2, 4, and 6).
Further, to confirm assembly and budding of BLV VLPs at
the plasma membrane, infected Sf cells were fixed, em-
bedded, and processed for thin-section electron micros-
copy as before. Some tubular forms of Gag were present
at the cell surface as observed previously for wild-type
BLV Gag (Kakker et al., 1999), but all BLV Gag variants
analysed showed evidence of abundant VLP formation
at the plasma membrane (representative data from
AcBgag49–51, AcBgag68–70, and AcBgag49–51,68–72-infected
cells are shown in Fig. 5, panels A–C, respectively). Thus,
in contrast to the data obtained with SIV Gag, deletion of
three to five residues in one and/or both of the presumed
interfaces of the BLV MA trimer did not affect assembly
and budding of BLV Gag VLPs.
Mutagenesis at the proposed BLV MA trimer–trimer
interface does not affect VLP assembly
The data obtained by mutagenesis of the proposed
monomer–monomer contacts in BLV MA cast doubt on
the relevance of a trimeric intermediate for BLV Gag
assembly. To further investigate the role of any MA de-
pendent trimer, a residue predicted to be at the inter–
trimer interface was also mutated and the effect on BLV
VLP assembly examined. The BLV MA trimer model fea-
tures an electrostatic interaction between the side
chains of Asp17 and Arg27 on adjacent trimers. Hydropho-
bic interactions between Leu19, Leu22, and Leu84 located
on the surface of the trimer were proposed to further
stabilise these interactions (Matthews et al., 1996). To
analyse the role of Asp17 in assembly, a recombinant
virus AcBgagD17L was constructed encoding BLV Gag
protein incorporating amino acid substitution Asp17 to
Leu. Sf9 cells infected with recombinant virus AcBgagD17L
was assessed for expression of mutant Gag protein and
particle formation as described. Infected cells expressed
BLV Pr44Gag with the same electrophoretic mobility as the
other mutants when analysed by Western blot (Fig. 4,
lane 7). Moreover, antigen was present in the superna-
tant of infected cells with no apparent diminution in the
efficiency of VLP release when compared to other BLV
Gag mutants (Fig. 4, lane 8). In addition, thin-section
FIG. 5. Thin-section electron micrographs of infected Sf cells show-
ing assembly and budding of mutant BLV Gag virus-like particles. The
cells were infected with recombinant baculoviruses expressing BLV
Gag49–51 (A); BLV Gag68–70 (B); BLV Gag49–51,68–72 (C); and BLV GagD17L
(D). The bar represents 100 nm.
FIG. 4. Western blot analysis of representative mutant BLV Gag
expression and particle release in insect cells. Cell lysate and super-
natant samples were resolved by 10% SDS–PAGE and immunoblotted
using a rabbit anti-BLV serum. BLV Gag49–51 in the cell lysate (lane 1)
and supernatant (lane 2); BLV Gag68–70 in the cell lysate (lane 3) and
supernatant (lane 4); BLV Gag49–51,68–72 in the cell lysate (lane 5) and
supernatant (lane 6); BLV GagD17L in the cell lysate (lane 7) and super-
natant (lane 8); wild-type AcMNPV infected cells (lane 9) and superna-
tant (lane 10). Presence of BLV Pr44Gag is indicated by an arrowhead.
The position of molecular weight markers is indicated on the left.
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electron microscopy demonstrated assembly and re-
lease of VLPs at the plasma membrane of AcBgagD17L-
infected cells (Fig. 5D). These results clearly indicate that
the identity of residue 17 of BLV MA is not crucial to the
assembly and release of Gag VLP.
BLV MA-CA is monomeric in solution
HIV MA and MA-CA have also been shown to exist as
a trimer in solution in low (150 mM) salt concentration
(Morikawa et al., 1998), providing direct experimental
support for the role of trimeric Gag in the assembly of
HIV and SIV. To date, however, no data exist on the
oligomeric intermediates of BLV MA or MA-CA in solu-
tion. In light of the data obtained by site-specific mu-
tagenesis of BLV MA in the present study and to further
address the question of the role of MA in BLV Gag
oligomerisation, BLV MA-CA was analysed by glycerol
velocity gradient sedimentation under conditions in
which trimeric HIV MA and MA-CA were reported
(Morikawa et al., 1998).
BLV MA-CA was expressed in Sf cells as a GST fusion
protein following infection with the recombinant baculo-
virus AcGST.Bma-ca. Following cell lysis, recombinant
GST-MA-CA protein was captured by glutathione-affinity
chromatography and the 36-kDa MA-CA domain re-
leased from the immobilised protein by cleavage with
thrombin. Purified, soluble MA-CA was concentrated and
examined for oligomeric structure by sucrose velocity
gradient sedimentation. Gradients were fractionated and
analysed by SDS–PAGE and Western blot. BLV MA-CA
was found to migrate as a single band between the
marker proteins carbonic anhydrase (29 kDa) and bovine
serum albumin (66 kDa) with a calculated molecular
mass of40 kDa, equivalent to the monomeric form (Fig.
6B). These data suggest that, as inferred from the mu-
tagenesis data, the BLV MA-CA Gag protein is mono-
meric in solution, at least when fused to GST, under
conditions in which HIV MA or MA-CA is trimeric.
The results in this article demonstrate that deletion of
three amino acids (Gly45, Leu46, Ala47) at the monomer–
monomer interface of the SIV MA trimer in the context of
the complete Gag severely affect the assembly and re-
lease of SIV Gag VLPs from the plasma membrane of
expressing cells. Recombinant baculoviruses AcSgag45–47,
AcSgag45–46, or AcSgag45 expressing SIV Gag mutants
lacking amino acids Gly45, Leu46, Ala47; Gly45, Leu46 or
Gly45, respectively, expressed levels of a Gag protein
equivalent to wild-type encoded by AcSgag in cell ly-
sates. However, only the wild-type SIV Pr57Gag, Gag45,
and SIV Gag45–46 were detected in the supernatant of
cells infected with the respective recombinant baculovi-
ruses. Electron microscopic analysis of thin sections of
infected cells confirmed the absence of retrovirus-like
particle assembly in the case of Gag protein expressed
by AcSgag45–47. The association of the monomers within
the SIV and HIV trimers is unusual in that the monomer–
monomer interactions are held together by main chain
hydrogen bonds in which the identity of the amino acid
side chain is not crucial (Hill et al., 1996; Rao et al., 1995).
Small deletions maybe tolerated as they move the next
adjacent residue into the backbone hydrogen bonding
configuration. When the deletion removes all key resi-
dues, however, the juxtaposition of opposing monomeric
faces becomes incompatible with trimer alignment and
assembly fails. Although this interpretation of the SIV MA
deletions is consistent with a model of lentivirus assem-
bly in which trimerization of Gag via the MA domain is an
intermediate (Forster et al., 2000; Rao et al., 1995), other
explanations are also valid. Oligomeric intermediates in
the cytosol of Gag-expressing cells could represent a
pool of Gag that fails to target the plasma membrane
and is rapidly degraded (Tritel and Resh, 2000) and the
three amino acid deletion of SIV Gag expressed by
AcSgag45–47 could preferentially enter this pathway due
to significant conformational change. A specific role for
the MA driven Gag trimer in the SIV assembly pathway
therefore remains unproven and would allow for the
observations that viruses with deletions of essentially all
of the MA domain of Gag can assemble and bud (Reil et
al., 1998; Wang et al., 1998). Interestingly, the crystal
structure of a third lentiviral MA domain, that of equine
infectious anaemia virus, has been shown recently not to
be trimeric (Hatanaka et al., 2002), further suggesting
that the role of the SIV/HIV MA trimer in virus assembly
may have been overinterpreted.
A model for a BLV MA trimer, based on that of the SIV
MA, is plausible based on their similar monomeric struc-
tures obtained by NMR (Matthews et al., 1996) and an
additional trimeric model has been proposed for the
more distantly related M-PMV MA, implying a common
mechanism of assembly for type C and B/D retroviruses
(Conte et al., 1997). In the case of BLV, however, deletion
FIG. 6. Gradient analysis of purified BLV MA-CA purified as de-
scribed. The gradient was fractionated from the top and MA-CA was
identified by Western blot of each fraction using a rabbit anti-BLV serum
(bottom). Molecular weight markers sedimented in parallel were iden-
tified by SDS–PAGE and Coomassie blue staining (top). The peak
position of each marker used to calculate the oligomeric form of the
MA-CA fragment is shown above the top panel. Numbers to the right of
the top panel are molecular weight markers and are measured in
kilodaltons.
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of the predicted trimer interface in the context of full-
length BLV Gag (Lys49-Gln51 in one monomer and Gly68-
Arg72 in the other) did not prevent BLV Gag VLP assem-
bly. A further substitution of Asp17 by Leu in the proposed
inter–trimer region also failed to disrupt VLP assembly.
These results add further doubt to the generality of an
assembly model for retroviral Gag proteins in which the
trimerization of MA is an important driver of the process.
In in vitro virus assembly systems, spherical assemblies
of Gag protein with morphologies similar to those seen
in budding VLPs occur with CA protein with only a short
extension at the amino-terminus in place of the MA
domain (Gross et al., 1998; Wilk et al., 2001). Thus, while
genetic (Freed et al., 1994) and physical (Morikawa et al.,
1995) data support a role for MA in the assembly of HIV
virions, alternate pathways of assembly, led by the CA
domain, can predominate when MA sequences are de-
leted (Reil et al., 1998; Wang et al., 1998). Overall, our
data confirm that the precise role of the MA domain in
retrovirus assembly remains incompletely understood.
For example, the production of HIV by rodent cells ap-
pears blocked at the level of particle assembly and
release (Mariani et al., 2000, 2001), yet can be partially
overcome by substitution of the HIV MA domain with the
MA of a murine retrovirus (Reed et al., 2002). Our data
suggest that studies of the comparative pathways of
retrovirus assembly may allow the common underlying
mechanisms to be identified.
MATERIALS AND METHODS
Cells and viruses
Sf cells were propagated in suspension or monolayer
cultures at 28°C in TC-100 medium (GIBCO BRL, U.K.)
supplemented with 5% foetal bovine serum. Baculovirus
recombinants were produced using BacPAK-6 viral DNA
(Kitts and Possee, 1993) and propagated as described
(King and Possee, 1992). Foetal lamb kidney cells in-
fected with BLV (FLK/BLV cells) were kindly supplied by
L. Willems, Department of Biochemistry and Applied Bi-
ology, University of Brussels, Gembloux, Belgium.
DNA manipulations
DNA manipulations and general molecular biology
techniques were as described (Sambrook et al., 1989).
DNA fragments encoding mutated gag genes were pro-
duced by overlapping PCR (Higuchi et al., 1988) and
ligated into the Baculovirus transfer vector pAcYM1 (Mat-
suura et al., 1987) for construction of recombinant bacu-
loviruses. All DNA mutations and junction sites were
confirmed by dideoxy nucleotide sequencing (Sanger et
al., 1977) prior to use.
Clones
BLV and SIV full-length gag or their mutants were
amplified from the original clones, pBLVT-15 (De-
schamps et al., 1981) and p239SpSp5 (SIVmac239 iso-
late), respectively, to generate recombinant transfer vec-
tors as described. Recombinant transfer vector pAcGST-
Bma-ca was constructed by ligation of the PCR-amplified
972-bp BLV ma-ca fragment of BLV Gag into BamH1
restriction enzyme site of pAcG2T (Pharmingen, CA), a
baculovirus vector which encodes the cloned protein as
a fusion protein with GST, a 26-kDa tag at the N-terminus.
SDS–PAGE and Western blot analysis
Sf cells were harvested at 48 h postinfection (h.p.i.),
washed with phosphate-buffered saline, and treated with
lysis buffer (2.3% SDS, 10 mM Tris–HCl, pH 6.8, 5%
2-mercaptoethanol, 10% glycerol) as described else-
where (Hughes et al., 1993). Protein samples were elec-
trophoresed on 10 or 15% SDS–PAGE. For Western blot
analysis, proteins resolved by SDS–PAGE were electro-
phoretically transferred to Immobilon-P membrane (Mil-
lipore International) by standard blotting procedure (Tow-
bin et al., 1979). After electroblotting, the membrane was
blocked using 3% dried-milk powder in PBS and probed
with appropriately diluted specific antiserum (primary
antibody) in blocking buffer for 1 h. After three washes,
the membrane was incubated with the secondary anti-
body conjugated with alkaline phosphatase and the
bound antibody detected by NBT-BCIP (GIBCO BRL).
VLP purification from infected cell supernatants
Particulate material in the supernatant of infected cells
was isolated as described (Hughes et al., 1993). Briefly,
infected cell supernatants were harvested at 60 h.p.i. and
cells and cellular debris removed by low-speed centrif-
ugation. The clarified supernatant was then layered
above a 20% sucrose cushion in TE (10 mM Tris–HCl and
1 mM EDTA, pH 8.0) and centrifuged at 20,000 rpm for
2 h. The pellet from the high-speed centrifugation was
resuspended in TE before analysis by SDS–PAGE and
Western blot.
Velocity sedimentation analysis of BLV MA-CA
Samples (100 l) containing approximately 0.1–0.2 mg
of purified BLV MA-CA protein were layered onto linear
gradients of 15 to 30% glycerol (v/v) in 20 mM Tris (pH
7.4), 100 mM NaCl, 1 mM dithiothreitol, 0.5 mM EDTA.
The proteins were sedimented at 40,000 rpm for 72 h at
4°C in a SW41 rotor. Fractions of 0.5 ml each were
collected and numbered from the top. A set of marker
proteins were sedimented in parallel; carbonic anhy-
drase (29 kDa), serum albumin (66 kDa) and lactose
dehydrogenase (4 36 kDa 144 kDa). An aliquot of 10
l of each fraction was analysed by SDS–PAGE.
Electron microscopy
Infected Sf9 cells were harvested after 48 h.p.i. and
fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer,
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pH 7.2 for conventional embedding in araldite as de-
scribed previously (Hockley et al., 1988).
Antisera and enzyme conjugates
Rabbit anti-BLV sera was kindly supplied by D. Porte-
telle, Department of Microbiology, University of Brussels,
Gembloux, Belgium. Monkey anti-SIV serum (ADP 416,
antiserum to SIVmac 251) was obtained from the NIBSC
Centralized Facility for AIDS Reagents. Goat anti-rabbit
IgG (A-3687) and affinity-isolated rabbit anti-monkey IgG
(A-1929) alkaline phosphatase conjugates for use as
second antibodies were obtained commercially (Sigma
Inc.).
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